CD4⁺ T cells coordinate protective immunity against pathogens. However, how human CD4⁺ T cell memory is established and evolves following primary and repeated vaccinations remain incompletely understood. Using COVID-19 mRNA vaccination as a model, we tracked 50 distinct antigen-specific populations directly ex vivo with peptide–MHC class II tetramers in eight SARS-CoV-2–naïve individuals from pre-exposure baseline through memory time points after three mRNA doses. We showed that primary vaccination established the architecture of antigen-specific memory. Initial vaccination leveraged pre-existing memory while preferentially recruiting high-avidity T cells, establishing an immunodominance hierarchy dominated by a small subset of precursors. Booster vaccination refined both the magnitude and quality of T cell memory. It increased select populations and enhanced differentiation of subdominant CD4⁺ T cells. Populations that did not become more abundant after boosting retained their polyfunctional potential. Beyond establishing memory to the ancestral spike, vaccinations recruited cross-reactive T cells and increased the breadth of CD4+ T cell memory. Collectively, these findings reveal how human T cell memory evolves through sequential immunizations to generate a functionally diverse and broadly responsive memory repertoire against future viral challenges.
Yi-Hui Lai, Xi Su, Silina Awad, Asgar Ansari, Juneil Jang, Ali O. Saber, Huang-Wen Chen, Hannah Jung, Annesha Sarkar, Elizabeth M. Drapeau, Warren B. Bilker, Scott E. Hensley, Laura F. Su
Through a genome-wide forward CRISPR/Cas9 screen in interleukin-3 (IL3)-dependent Ba/F3 cells, we identified osteoclastogenesis-associated transmembrane protein 1 (OSTM1) as a previously unrecognized tumor suppressor. Analysis of patient datasets revealed that OSTM1 is frequently deleted or downregulated in human B-cell malignancies (BCM). In mice, Cd19-Cre-driven B cell–specific monoallelic or biallelic deletion of Ostm1 cooperated with Cdkn2a loss to drive lymphomagenesis with near-complete penetrance. Mechanistically, OSTM1 directly interacts with phosphodiesterase 3B (PDE3B) and promotes its proteasomal degradation. Because PDE3B hydrolyzes cyclic AMP (cAMP), loss of OSTM1 stabilizes PDE3B, leading to suppression of tumor-suppressive cAMP-dependent PKA/CREB signaling and promotion of oncogenic transformation. Consistent with this mechanism, PDE3B is frequently amplified or upregulated in BCM, and expression of CREB/CREBBP transcriptional targets correlates positively with OSTM1 expression but inversely with PDE3B across BCM cohorts. Importantly, silencing Pde3b reverses oncogenic transformation driven by Ostm1 loss. Together, these findings establish OSTM1 as a tumor suppressor and uncover an OSTM1/PDE3B/cAMP signaling axis that restrains B-cell lymphomagenesis and may represent a therapeutically actionable vulnerability.
Muhammad Usama Tariq, Namratha Sheshadri, Jianliang Shen, Jaeyong Jung, Rongrong Li, Hassan Sajjad, Mark C. Koch, Kevin Lu, Junrong Yan, Barbara Rosati, Giuseppe Caso, Brinda Vallat, Stephen K. Burley, Jun Wang, Christina Glytsou, Yi Sun, Tong Liu, Hong Li, Suzie Chen, Jiekun Yang, Zhiyuan Shen, Richard Z. Lin, Christian S. Hinrichs, Francesco Bertoni, Y. Lynn Wang, Jean Vacher, Ping Xie, Wei-Xing Zong
Dan Wang, Wenbin Ye, Jingjing Lyu, Xinzhi Hu, Weifan Yin, Dadmehr Yaghoubi, Chaorong Chen, Ran Jing, Ravi Dave, Qin Yang, Ya Cui, Tamer Sallam
Neurogenic inflammation is one component that sculpts the immune milieu of solid tumors. However, it remains unclear how the sensory-neuroimmune axis shapes the immune microenvironment in cold tumors to bolster treatment resistance. Using orthotopic head and neck squamous cell carcinoma (HNSCC) models, we demonstrate tumor growth-induced sensory hyperexcitability, and that surgical sensory signaling interruption reduced tumor growth. Genetic knockout of a key neuropeptide released by sensory neurons, calcitonin gene-related peptide (CGRP), encoded by Calca, produced eradication when paired with radioimmunotherapy. Such treatment reduced Treg infiltration and immunosuppressive function in Calca knockout mice. We also observed that high-dose psilocybin functions as a CGRP inhibitor and transiently reduces tumor growth by increasing antitumor immunity. Additionally, psilocybin increased circulating serotonin, which was partially reversed with platelet activation inhibitor, clopidogrel. We observed differential effects on CD8 and Treg functionality by psilocin in vitro. Correlational analyses in plasma from human subjects following a single-dose psilocybin corroborated these findings. Together, this work underscores the complex interaction of neurogenic inflammation and the tumor immune microenvironment, highlighting a potential therapeutic avenue for HNSCC and other solid tumors.
Shaquia L. Idlett-Ali, Alexander T.H. Nguyen, Khalid N.M. Abdelazeem, Diemmy Nguyen, Nicholas A. Olimpo, Michael Knitz, Jacob Gadwa, Tyler Weiskpof, Chloe Hodgson, Harshita Kumar, David Ceja Galindo, Teddi Gray, Sidharth V. Puram, Daniel L. Miller, Ginger E. Nicol, Anthony J. Saviola, Douglas G. Osborne, Sana D. Karam
Donor-specific transplantation tolerance promises to free recipients from complications associated with lifelong immunosuppression. Anergy, a CD4+ conventional T cell (Tconv)-intrinsic state of long-term hypofunction, is thought to arise when T cells encounter cognate antigen in the absence of costimulation. Anti-CD154 (αCD154), an antibody that blocks T cell costimulation and is currently in clinical trials, can induce donor-specific transplantation tolerance in mice in association with anergy of Tconvs recognizing persistently expressed alloantigens. Using murine models of fully mismatched cardiac allograft tolerance or repeated alloantigen exposure, we demonstrate that αCD154 is not sufficient and regulatory T cells (Tregs) are necessary to induce and sustain αCD154-mediated alloreactive Tconv anergy. Transient depletion of Tregs disrupted the induction of αCD154-mediated Tconv anergy, and in mice with established tolerance, Treg depletion transcriptionally and functionally reinvigorated previously anergic Tconvs. Mechanistically, Treg depletion increased IL-2 availability and IL-2R signaling in Tconvs, and exogenous IL-2 could bypass Treg-mediated control to partially restore Tconv function. Thus, the state of αCD154-mediated Tconv anergy is less cell-intrinsic than previously thought and requires Tregs to limit IL-2 availability for both its induction and its continuous enforcement. Selecting immunosuppressive drugs that preserve this Treg function may be critical for achieving stable clinical transplantation tolerance.
Alexandra Cassano, Domenic Abbondanza, Ying Wang, Shuang Wu, Christine M. McIntosh, Peter Wang, Jennifer B. Allocco, Montserrat Kwan, Ricardo Mora-Cartin, Ephraim Craddock, Michael S. Andrade, Anita S. Chong, Maria L. Alegre
Mitochondrial failure is a convergent driver of neuronal aging and neurodegeneration, yet upstream factors that link age-associated changes to mitochondrial homeostasis remain incompletely defined. Melatonin, which is synthesized within neuronal mitochondria, declines with age and is further exacerbated in several neurodegenerative disorders. Here we show that endogenous melatonin is required to maintain cerebral mitochondrial biogenesis and mitochondrial quality through the SIRT1/PGC-1α signaling axis. Across young (8-week), adult (20-week), and middle-aged (1-year) mouse brains, aging was associated with reduced SIRT1/PGC-1α, decreased mtDNA copy number, and diminished abundance of oxidative phosphorylation proteins. Human hippocampal samples from older donors similarly exhibited reduced SIRT1/PGC-1α but retained mitochondrial protein abundance while accumulating oxidatively damaged mitochondria and showing reduced LC3B, consistent with impaired mitochondrial quality control. In aralkylamine N-acetyltransferase knockout (AANAT-KO) mice, endogenous melatonin deficiency suppressed SIRT1/PGC-1α, NRF1, and TFAM in an age-dependent manner, reduced mtDNA and mitochondrial transcript abundance, lowered mitochondrial protein levels, and increased mitochondrial oxidative damage. Melatonin supplementation restored the biogenesis program, increased mtDNA and mitochondrial transcripts, and rescued respiratory chain protein abundance. Finally, mitochondrial transplantation experiments indicated that mitochondrial quality contributes to neuronal integrity. Melatonin-deficient mitochondria induced neurite degeneration in wild-type neurons, whereas wild-type mitochondria rescued neurite architecture and improved survival in melatonin-deficient neurons. Together, these findings identify endogenous melatonin as a regulator of cerebral mitochondrial biogenesis and suggest that melatonin decline contributes to mitochondrial-mediated neuritic degeneration and neuronal loss.
Abhishek Jauhari, Sergei V. Baranov, Adam C. Monek, Tanisha Singh, Fang Li, Mary A. Pickford, Yalikun Suofu, Diane L. Carlisle, Robert M. Friedlander
Despite recent therapeutic advances, the prognosis of patients with metastatic clear cell renal cell carcinoma (ccRCC) remains poor, and the molecular mechanisms driving metastasis are not fully understood. Herein, we identify forkhead box transcription factor A2 (FOXA2) as a key regulator of ccRCC metastasis. FOXA2 expression is elevated in metastatic ccRCC and correlates with adverse clinical outcomes. Functional assays show that FOXA2 enhances ccRCC cell invasion and metastasis both in vitro and in vivo. Mechanistically, FOXA2 recruits the histone acetyltransferase HAT1 as a transcriptional coactivator to upregulate growth differentiation factor 15 (GDF15) expression, which in turn activates GFRAL/RET-mediated STAT3 signaling and the epithelial-to-mesenchymal transition (EMT), thereby driving metastasis through both autocrine and paracrine pathways. Moreover, tumor cell-secreted GDF15 facilitates CD8+ T cell exhaustion within the tumor microenvironment, contributing to immune evasion and resistance to anti-PD-1 therapy. Importantly, pharmacologic inhibition of this pathway using either the GDF15-neutralizing antibody ponsegromab or the RET inhibitor pralsetinib markedly impairs FOXA2-driven metastasis and synergizes with anti-PD-1 therapy. Together, our findings delineate a FOXA2–GDF15–STAT3 signaling axis that orchestrates metastatic progression and immune suppression in ccRCC and suggest promising therapeutic strategies for patients with advanced disease.
Cong Huang, Rui Rui, Heng Guo, Anbang He, Wenzhi Gao, Jian Fan, Cuijian Zhang, Yanqing Gong, Liqun Zhou, Xuesong Li, Shiming He
BACKGROUND. Molecular subtyping may offer a promising path toward a unified framework for precision oncology. We sought to characterize the patterns of programmed cell death (PCD), a pivotal cellular process shaping both intrinsic tumor malignancy and the tumor microenvironment, to better understand tumor heterogeneity. METHODS. We performed integrative multi-cohort transcriptomic analyses encompassing four canonical PCD modes across multiple cancer types. We identified PCD subtypes using nonnegative matrix factorization (NMF), characterized their molecular features and clinical relevance, and developed a streamlined 20-gene classifier to facilitate subtype assignment. RESULTS. We identified five conserved PCD subtypes with distinct genomic alterations, cellular stresses, malignant traits, prognostic outcomes, and immune landscapes. In the immunotherapy setting, PCD subtypes were associated with distinct outcomes across multiple cancer types, with the pyroptosis-dominant (PCD-P) subtype showing the most favorable outcomes. The 20-gene classifier showed good discriminatory performance across independent cohorts. Finally, we proposed candidate subtype-specific therapeutic strategies. CONCLUSION. This study establishes a comprehensive framework for characterizing PCD patterns in cancer, laying the groundwork for biomarker discovery and rational therapeutic design that warrant future evaluation of efficacy and toxicity. FUNDING. National Key R&D Program of China; National Natural Science Foundation of China; Fundamental Research Funds for the Central Universities, Sun Yat-sen University; HE Science Foundation; Young Talents Program of Sun Yat-sen University Cancer Center; Academician Workstation of Jun Ma; Specific Research Fund of the Innovation Platform for Academicians of Hainan Province; Shenzhen Medical Research Fund; Guangdong Basic and Applied Basic Research Foundation.
Zi-Wei Huang, Zi-Han Wang, Yi Liu, Jia-Yi Shen, Yan-Ling Wu, Zi-An Fang, Dong-Hong Wu, Yi-Zhe Cheng, Jing-Jing Zhang, Xiong Zou, Jun Ma, Jiawei Lv, Shuang Wang, Yu-Pei Chen
Ibrutinib, a Bruton's tyrosine kinase inhibitor, is indicated for treating chronic lymphocytic leukemia (CLL), but hypertension is a common cardiovascular adverse event. Previous studies have linked ibrutinib to cardiac events through dysregulated intracellular calcium handling, but the mechanisms underlying ibrutinib-associated hypertension remain largely unknown. Here, we followed up 225 CLL patients receiving ibrutinib or managed with watch-and-wait strategy, and identified ibrutinib as an independent risk factor for hypertension. In mice, ibrutinib elevated arterial blood pressure (BP) without structural remodeling of small arteries, and it potentiated K+-induced vasoconstriction. In vascular smooth muscle cells (VSMCs), ibrutinib upregulated CaV1.2 channel expression and function, as evidenced by enhanced CaV1.2 currents and K+-triggered-[Ca2+]i elevation. Mechanistically, ibrutinib suppressed casein kinase 2 (CK2)-mediated HSP90β phosphorylation, and stabilized C/EBP-β, which bound to the promoter of Cacna1c gene and drove CaV1.2 transcription. Significantly, C/EBP-β knockdown attenuated ibrutinib-induced CaV1.2 hyperactivity and vasoconstriction. Collectively, these findings reveal a CK2-HSP90β-C/EBP-β-CaV1.2 signaling cascade through which ibrutinib enhances vascular Ca2+ influx and vasoconstriction, thereby elevating arterial BP. Thus, this study nominates C/EBP-β as a therapeutic target for ibrutinib-associated hypertension.
Ludan Zhang, Shumin Yin, Wei Hou, Dan Yang, Yiyuan Jia, Yun Liu, Yan Wang, Sirui Zhao, Xiaoyan Gao, Xiaolin Sun, Xiao Lu, Jianyong Li, Ming Chu, Xiaoqing Xiong, Huayuan Zhu, Juejin Wang
BACKGROUND. Alport syndrome (AS), a Mendelian kidney disease, is caused by pathogenic mutations in the X- linked gene COL4A5 and autosomal genes COL4A3, COL4A4 encoding the alpha-chains secreted by podocytes to form the glomerular basement membrane collagen α3α4α5(IV) trimer. Nonsense mutations in autosomal recessive and hemizygous X-linked Alport syndrome (NMAS) introduce premature termination codons and have a particularly poor prognosis, with kidney failure typically occurring by early adulthood. There is substantial unmet need for effective therapy for AS, which has no approved treatments. Exaluren (formerly ELX-02) is a novel eukaryotic ribosome-targeted glycoside that is preferentially taken up by kidney cells and promotes readthrough of premature but not native termination codons, allowing full-length protein production. METHODS. In this proof-of-mechanism study, three patients (ages 12–18) with autosomal recessive Alport syndrome and a COL4A4 premature termination codon received daily subcutaneous exaluren (0.75 mg/kg) for 8 weeks. RESULTS. Safety and tolerability assessments (primary endpoint) revealed no new signals. Secondary endpoints assessed by kidney biopsy before and after treatment revealed increased collagen α3(IV), α4(IV) and α5(IV) abundance, physiologically localised collagen α5(IV), and partially improved podocyte morphology in all participants, with changes directionally concordant with increased collagen α3α4(IV) abundance. Proteinuria changes were inconsistent with interpretation limited by intra-patient variability and the short treatment duration; hematuria persisted in all participants. CONCLUSION. These findings provide first-in-human evidence of exaluren-mediated collagen IV readthrough and justify further trials in Alport syndrome and other nonsense mutation-driven kidney diseases, which often cause early-onset kidney failure. TRIAL REGISTRATION. ClinicalTrials.gov Identifier: NCT05448755.
Daniel P. Gale, Detlef Böckenhauer, Maryline Fresquet, Emily Williams, Conor J. Sugden, Melanie M.Y. Chan, Katie Wong, Meei-Hua Lin, Kohei Omachi, Konstantinos Tzoumkas, Lior Horonchik, Roger B. Clark, Jochen Reiser, Peter Mundel, Uwe Andag, Jeffrey H. Miner, Rachel Lennon, Nicole Endlich, Behzad Najafian, Sumit Aggarwal
No posts were found with this tag.